Drug Prices

Pill illo
Pharmalot

As pharma seeks more orphan drug designations, FDA fails to assess important needed info

By Ed Silverman

Pharmalot

Pharmalittle: Merck boosts prices on a few drugs; former Insys execs pleads guilty in Subsys conspiracy

By Ed Silverman

Generic epinephrine
Pharmalot

FDA promised a ‘lower-cost option’ to EpiPen, but the price isn’t any lower

By Ed Silverman

Pharmalot

Pharmalittle: AbbVie sues U.K. over hepatitis C drug program; pharma braces for pricing proposals from Democrats

By Ed Silverman

Humira
Pharmalot

AbbVie offers a ‘huge’ discount on Humira to fend off European rivals

By Ed Silverman

Pharmalot

Pharmalittle: Trump to give speech today on drug pricing; FDA approves a novel, but pricey flu drug

By Ed Silverman

Clinical Trial pricing
Pharmalot

Here’s a hypothesis: Lower doses of some cancer pills could save a lot of money

By Ed Silverman

Pharmalot

Mallinckrodt will be honored for research into a drug that causes sticker shock

By Ed Silverman

Insulin NOVO NORDISK
Pharmalot

Minnesota becomes first state to sue major insulin makers over price-gouging

By Ed Silverman

Pharmalot

Pharmalittle: Trump to require drug prices in ads; Europe cracks down on valsartan ingredients maker

By Ed Silverman

Pharmalot

Pfizer pays $700,000 to settle charges over misleading copay coupons

By Ed Silverman

Pharmalot

CVS sets a cost-effectiveness threshold for health plan coverage of most new drugs

By Ed Silverman

Injectable drugs
Pharmalot

Trump plan to give private Medicare leverage over drug costs would boost PBMs and biosimilars

By Ed Silverman

Rep. Greg Walden
Pharmalot

Republican lawmakers want FTC to probe PBM mergers over drug pricing concerns

By Ed Silverman

Pharmalot

A federal appeals court just slammed the door on Allergan’s deal with the Mohawk tribe

By Ed Silverman

Pharmalot
Pharmalot

U.K. health officials make a counteroffer to Vertex for its pricey cystic fibrosis drugs

By Ed Silverman

Pharmalot
Pharmalot

Under pressure from Trump, Pfizer agrees to roll back price hikes

By Ed Silverman

Prison
Pharmalot

Can a federal drug discount program unlock savings for state prisons?

By Ed Silverman

Pharmalot
Pharmalot

Aetna pressures whistleblower who alleged CVS Caremark ripped off Medicare

By Ed Silverman

Pharmalot

Pharmalittle: Amgen migraine drug costs less than expected; J&J halts development on Alzheimer’s drug

By Ed Silverman

Prescription Medication
Pharmalot

AbbVie and J&J reverse course on a price hike in face of criticism

By Ed Silverman

Drug Prices
Pharmalot

Martin Shkreli was hardly an outlier when it came to jacking up prices on older drugs

By Ed Silverman

Drug Prices
Pharmalot

U.S. spending on prescription drugs rose less than 1 percent last year

By Ed Silverman

Pharmalot

Pharmalittle: Amgen migraine drug show promise; DEA moves to tighten opioid rules

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi warns Canada over industry treatment; Pfizer got a big boost from the new tax law

By Ed Silverman

Gilead Sciences
Pharmalot

Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?

By Ed Silverman

NIH headquarters
Pharmalot

NIH is urged to probe Aegerion patents for failing to disclose federal funding

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer paid its CEO how much? Glaxo says Brexit will not be cheap

By Ed Silverman

Clogged Artery
Biotech

Wall Street reacts to Regeneron, Sanofi cholesterol drug study results

By Adam Feuerstein and Damian Garde

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy